ongo
coronaviru
diseas
pandem
seriou
threat
global
public
health
impos
sever
burden
entir
human
societi
sever
acut
respiratori
syndrom
sar
caus
sever
respiratori
ill
death
current
specif
antivir
drug
treat
sever
vaccin
activ
develop
research
group
around
world
surfac
spike
protein
highli
express
intern
n
nucleocapsid
protein
wide
consid
promis
candid
vaccin
order
guid
design
effect
vaccin
need
experiment
data
potenti
epitop
candid
studi
map
immunodomin
id
site
protein
use
sera
sampl
collect
recent
discharg
patient
specif
antibodi
level
sera
recov
patient
strongli
correl
neutralis
antibodi
titr
use
epitop
map
determin
landscap
id
site
protein
identifi
nine
linear
b
cell
id
site
four
nine
id
site
found
receptorbind
domain
rbd
analysi
show
id
site
potenti
highaffin
antibodi
bind
site
peptid
contain
two
nine
site
test
vaccin
candid
mous
model
detect
epitopespecif
antibodi
activ
immunis
mice
studi
first
time
provid
human
serolog
data
design
vaccin
coronaviru
diseas
novel
infecti
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
first
emerg
decemb
sinc
becom
worldwid
pandem
infect
far
led
million
case
million
death
across
although
put
epitop
bind
antibodi
report
epitop
high
affin
need
identifi
inform
epitop
would
use
particularli
regard
human
immunolog
bia
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
immunodomin
id
might
restrict
immun
respons
immunodomin
phenomenon
immunogen
variat
among
distinct
immunogen
antigen
site
immunogen
demonstr
cell
b
cell
phenomenon
restrict
develop
effect
vaccin
influenza
highli
variabl
virus
method
use
overcom
manipul
viral
immun
restrict
reli
landscap
immunodomin
therefor
crucial
map
immunogen
landscap
potenti
epitop
protein
acceler
develop
identifi
five
linear
immunodomin
id
site
protein
induc
neutralis
antibodi
contrari
rbd
found
contain
major
neutralis
epitop
protein
id
site
studi
aim
map
landscap
id
site
within
protein
compar
result
counterpart
sarscov
unlik
sarscov
found
rbd
linear
id
site
sera
sampl
collect
recent
discharg
patient
subsequ
microneutralis
test
demonstr
mice
immunis
peptid
contain
id
site
within
rbd
produc
neutralis
antibodi
taken
togeth
rbd
differ
id
landscap
counterpart
sarscov
furthermor
data
provid
guidanc
design
proteinbas
sar
vaccin
might
avoid
advers
reaction
diseaseenhanc
effect
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
immun
respons
antivir
effect
serum
patient
serum
sampl
patient
test
posit
elisa
assay
use
plate
coat
lysat
figur
profil
igg
igm
iga
spike
n
nucleocapsid
protein
show
patient
elev
antibodi
titr
compar
healthi
donor
figur
g
gener
high
igg
titr
n
protein
present
sera
secondari
infect
need
consid
also
analys
correl
n
proteinspecif
antibodi
level
test
id
site
rbd
fragment
could
use
potenti
vaccin
mice
found
epitopesproteinspecif
antibodi
titr
exceed
microneutralis
titr
sever
order
magnitud
consid
rel
low
neutralis
antibodi
level
recov
patient
studi
previou
report
reason
expect
signific
differ
specif
antibodi
neutralis
antibodi
found
equival
antivir
activ
immunis
epitop
compar
immunis
entir
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
rbd
fragment
figur
provid
evid
epitopebas
vaccin
could
offer
compar
protect
compar
subunit
vaccin
potenti
better
safeti
also
compar
bind
residu
previous
identifi
neutralis
antibodi
id
epitop
id
site
rbd
found
histopatholog
chang
even
result
provid
limit
inform
id
still
know
effect
target
immunodomin
still
need
understand
mechan
underli
phenomenon
immun
control
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
glycosyl
site
id
sarscov
id
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
